Page 44 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat
P. 44
How does sequential therapy: sorafenib and regorafenib play roles in
optimizing advanced HCC treatment outcome?
Abstract:
Not long ago, there were no systemic treatments for patients with hepatocellular carcinoma (HCC) whose
disease progresses during sorafenib treatment. Now regorafenib is one of the well-proved sequential
treatments shown to provide survival benefit in advanced HCC patients progressing on sorafenib treatment.
In RESORCE study (a randomized, double-blind, parallel-group, phase 3 trial done at 152 sites in 21
countries) It has successfully proved that regorafenib improved overall survival with hazard ratio of 0·63
(95% CI 0·50–0·79; one-sided p<0·0001); median survival was10·6 months (95% CI 9·1–12·1) for
regorafenib versus 7·8 months (6·3–8·8) for placebo. After the publication of RESORCE study, more and
more studies have demonstrated consistent safety and effectiveness profile of sorafenib - regorafenib in real-
life settings. With the robust evidence, international treatment guidelines for hepatocellular carcinoma (HCC)
have recommended oral multikinase inhibitor sorafenib and regorafenib ones of the treatment options in
advanced HCC treatment. Dr. Shao will share the current treatment perspective in HCC treatment, recent
advances in the role of sorafenib and regorafenib, and how does sequential therapy: sorafenib and
regorafenib play roles in optimizing advanced HCC treatment outcome?
